Wilms1 Cells
USD$800.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The Wilms1 cell line was derived from a primary Wilms tumor sample obtained from a patient presenting with large bilateral kidney tumors, indicative of Wilms tumor, a pediatric nephroblastoma. This cell line harbors a homozygous nonsense mutation in the WT1 gene (c.149 C>A, p.S50X), which results in a truncated and non-functional WT1 protein. The WT1 gene, critical for kidney development and function, is frequently mutated in Wilms tumor, particularly in those with a stromal subtype that exhibits ectopic mesenchymal differentiation. Wilms1 cells, therefore, represent a unique in vitro model for studying the consequences of WT1 loss of function in tumor biology. The Wilms1 cell line maintains a stable karyotype with no significant chromosomal abnormalities, allowing for reliable long-term culture. These cells exhibit a mesenchymal phenotype, characterized by the expression of vimentin and the absence of epithelial markers such as cytokeratin, consistent with their stromal origin. Additionally, the cell line demonstrates limited but notable mesenchymal differentiation capacity, including the ability to differentiate into muscle-like cells under appropriate conditions. This makes Wilms1 an invaluable tool for investigating the molecular mechanisms of mesenchymal differentiation and its deregulation in Wilms tumor pathogenesis. Wilms1 has also been used to study the activation status of key signaling pathways involved in tumor progression. Proteomic analyses have shown that Wilms1 cells exhibit phosphorylation and activation of several receptor tyrosine kinases, including EGFR and PDGFRβ, as well as downstream MAPK signaling pathways. These findings highlight the relevance of the Wilms1 cell line in exploring targeted therapeutic approaches for Wilms tumor by dissecting the role of these pathways in cancer cell survival, proliferation, and differentiation. |
|---|---|
| Organism | Human |
| Tissue | Kidney |
| Applications | In vitro cell culture model. Biochemical studies |
| Synonyms | Wilms1-2l |
Characteristics
| Age | 2 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Morphology | Spindle-shaped |
| Cell type | Wilms cells |
| Growth properties | Adherent |
Regulatory Data
| Citation | Wilms1 (Cytion catalog number 300411) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_A5SC |
Biomolecular Data
| Receptors expressed | Receptor tyrosine kinases EGFR, EphA7, PDGFRalpha, FGFR1, PDGFRbeta, AxL |
|---|---|
| Tumorigenic | Yes, in nude mice. Forms tumor with small cells consistent with Wilms' tumor (xenografts may not represent Wilm’s tumors completely, see E. Kunce Stroup 2017) |
| Viruses | HIV-1: negative, HBV: negative, HCV: negative |
| Mutational profile | WT1 mutation status: homozygous c. 149 C>A, p.S50x, LOH: 11p11-11pter, CTNNB1 mutation status: heterozygous TCT>TTT, p.S45F |
| Karyotype | 46, normal |
Handling
| Culture Medium | MSCGM kit (from Lonza) |
|---|---|
| Dissociation Reagent | Accutase |
| Doubling time | 24 hours |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Seeding density | 1 x 104 cells/cm2 |
| Fluid renewal | 1 to 2 times per week |
| Post-Thaw Recovery | Fast |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300411-130524 | Certificate of Analysis | 23. May. 2025 | 300411 |
| 300411-221 | Certificate of Analysis | 23. May. 2025 | 300411 |
-
Related products
Related products